Skip to main content
Caplight Logo









Ingenium Therapeutics

Ingenium Therapeutics

Private
DaejeonHealthcare & Life Scienceshttps://ingeniumcell.co.kr/

Last Round

Series A

Nov 21, 2023

Total Funding Raised

$8.91M

Company Overview

Ingenium Therapeutics is a biotechnology company that develops next-generation cancer therapies based on innate immunity and NK cells for treatments of leukemia and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

allogeneic cell therapyCAR-iNKToff-the-shelf cell therapycell therapycancer immunotherapyiNKT cell therapysolid tumorshematological malignanciesblood cancerout-licensingpreclinical biotechNK cell therapyGraft-versus-Host DiseaseGvHDCytokine Release SyndromeCRSOrphan Drug Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ingenium Therapeutics Comparables

Compare Ingenium Therapeutics with similar companies based on industry and business-model similarity.

Ingenium Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cure Genetics
81%
Arovella Therapeutics Ltd
79%
BrightPath Biotherapeutics Co., Ltd.
78%

Ingenium Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 21, 2023
Pre SeedApr 1, 2022

Ingenium Therapeutics Investors

Notable investors and investment history

Ingenium Therapeutics investors
InvestorRounds
K-Ground VenturesSeries A
Daewoodang HealthcareSeries A
Capstone Partners KoreaSeries A
Laplace PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 21, 2023

    $4.05M round led by Capstone Partners Korea.

  • Apr 1, 2022

    $4.86M raised in Pre Seed round.

Ingenium Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ingenium Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ingenium Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDaejeon
Year Founded2020
Last FundingNov 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?